Slagle Financial’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$221K Sell
1,747
-38
-2% -$5.01K 0.07% 124
2026
Q1
$249K Sell
1,785
-131
-7% -$18.3K 0.08% 107
2025
Q4
$235K Sell
1,916
-324
-14% -$39.4K 0.08% 105
2025
Q3
$249K Sell
2,240
-30
-1% -$3.41K 0.09% 101
2025
Q2
$252K Sell
2,270
-66
-3% -$7.02K 0.1% 99
2025
Q1
$262K Sell
2,336
-25,788
-92% -$2.66M 0.12% 88
2024
Q4
$2.6M Buy
28,124
+1,100
+4% +$99K 1.17% 32
2024
Q3
$2.27M Buy
27,024
+1,347
+5% +$103K 1.01% 40
2024
Q2
$1.76M Buy
25,677
+1,055
+4% +$70.4K 0.9% 49
2024
Q1
$1.8M Sell
24,622
-26,508
-52% -$2.04M 0.98% 44
2023
Q4
$2.07M Buy
51,130
+25,438
+99% +$1.98M 1.19% 37
2023
Q3
$1.93M Buy
25,692
+1,227
+5% +$94.4K 1.18% 31
2023
Q2
$1.89M Buy
+24,465
New +$1.95M 1.17% 35

Other funds holding GILD

Slagle Financial's GILD Position: Q2 2026 in Review

Slagle Financial reduced its Gilead Sciences (GILD) stake by 2.1% in Q2 2026, selling an estimated $5.01K and leaving 1,747 shares worth $221K. The position accounts for 0.07% of the portfolio, ranked #124.

Slagle Financial first reported a position in GILD in Q2 2023 and has held it in 13 quarters since. The position peaked at $2.6M in Q4 2024. 1,032 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Slagle Financial held 1,747 shares of Gilead Sciences worth $221K as of Q2 2026.
  • Slagle Financial sold 38 Gilead Sciences shares in Q2 2026, an estimated $5.01K.
  • Gilead Sciences made up 0.07% of Slagle Financial's portfolio in Q2 2026, its #124 holding.
  • Slagle Financial first reported a position in Gilead Sciences in Q2 2023 and has held it in 13 quarters since.
  • Slagle Financial's Gilead Sciences position peaked at $2.6M in Q4 2024.
  • 1,032 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Slagle Financial's 13F filing for Q2 2026, filed 29 Jul 2026.